The publication of Phase I analyses for Merck & Co.'s Alzheimer's therapy, verubecestat, may help to explain why the company decided to pursue costly Phase III studies without more data – but questions still remain around the drug's fundamental hypothesis that modulating the brain amyloid system will translate into a clinical response.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers Between Academia And Industry column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Pharmaceuticals, and Medical Devices sectors.